- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04335786
Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease
PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease
Rationale: The current SARS-CoV-2 pandemic has a high burden of morbidity and mortality due to development of the so-called acute respiratory distress syndrome (ARDS). The renin-angiotensin-system (RAS) plays an important role in the development of ARDS.
ACE2 is one of the enzymes involved in the RAS cascade. Virus spike protein binds to ACE2 to form a complex suitable for cellular internalization. The downregulation of ACE2 results in the excessive accumulation of angiotensin II, and it has been demonstrated that the stimulation of the angiotensin II type 1a receptor (AT1R) increases pulmonary vascular permeability, explaining the increased lung pathology when activity of ACE2 is decreased. Currently available AT1R blockers (ARBs) such as valsartan, have the potential to block this pathological process mediated by angiotensin II. There are presently two complementary mechanisms suggested: 1) ARBs block the excessive angiotensin-mediated AT1R activation, and 2) they upregulate ACE2, which reduces angiotensin II concentrations and increases the production of the protective vasodilator angiotensin 1-7. In light of the above, ARBs may prevent the development of ARDS and avert morbidity (admission to intensive care unit (ICU) and mechanical ventilation) and mortality.
Objective: To investigate the effect of the ARB valsartan in comparison to placebo on the occurrence of one of the following items, within 14 days of randomization:1) ICU admission; 2) Mechanical ventilation; 3) Death.
Study design: A double-blind, placebo-controlled 1:1 randomized clinical trial Study population: Adult hospitalized SARS-CoV-2-infected patients (n=651). Intervention: The active-treatment arm will receive valsartan in a dosage titrated to blood pressure up to a maximum of 160mg b.i.d. and the placebo arm will receive a matching placebo also titrated to blood pressure. Treatment duration will be 14 days or up to hospital discharge < 14 days or occurrence of the primary endpoint if < 14 days.
Main study endpoint: The primary study endpoint is the occurrence within 14 days of randomization of either: 1) ICU admission; 2) Mechanical ventilation; 3) Death.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
's-Hertogenbosch, Netherlands
- Jeroen Bosch ziekenhuis
-
Arnhem, Netherlands, 6815AD
- Rijnstate
-
Nijmegen, Netherlands
- Radboudumc
-
Roermond, Netherlands
- Laurentius Ziekenhuis
-
Rotterdam, Netherlands
- Erasmus MC
-
Rotterdam, Netherlands
- Ikazia Ziekenhuis
-
Rotterdam, Netherlands
- Franciscus Gasthuis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Adult (age ≥ 18 years)
- Admitted to the hospital of any participating center
- Confirmed SARS-CoV-2 infection with either: positive laboratory test for SARS-CoV-2* ; or positive CT thorax diagnostic for SARS-CoV-2 infection according to the prevailing criteria
Randomization:
- Within 24 hours of confirmed in-hospital SARS-CoV-2 infection diagnosis OR
within 24 hours of hospital admission in case of pre-hospital confirmed SARS-CoV-2 infection.
- In case there is a lack of laboratory tests for SARS-CoV-2 in the participating center of the potentially eligible patient, a positive laboratory test for SARS-CoV-2 will be no longer required. In that case, the potentially eligible patient needs to meet the prevailing criteria for the diagnosis of SARS-CoV-2 infection of that participating center, such as typical abnormalities on pulmonary CT in the setting of high clinical suspicion of SARS-CoV-2 infection.
Exclusion Criteria:
- Admitted to ICU prior to randomization
- Currently taking an ARB or angiotensin-receptor-neprilysin-inhibitor (ARNI)
- Use of other investigational drugs at the time of enrollment
- Prior reaction or intolerance to an ARB or ARNI; or severe intolerance to an ACEi, defined as angio-oedema requiring medical intervention
- Systolic blood pressure < 105mmHg or diastolic blood pressure <65mmHg
- Potassium greater than 5.5 mEq/L within 4 weeks of study enrollment.
- Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 within 4 weeks of study initiation
- A known history of renal artery stenosis
- AST and/or ALT > 3 times the upper limit of normal within 4 weeks of study enrollment. In case of mild to moderate liver dysfunction valsartan dosage will be limited to a maximum of 80mg
- Severe liver dysfunction, biliary cirrhosis or cholestasis
- Severe volume depletion or severe acute kidney injury that, in the opinion of the investigator, would preclude administration of valsartan
- Concurrent treatment with Aliskiren
- Inability to obtain informed consent
- Pregnancy or breastfeeding
- In females of childbearing age, unwillingness to use birth control or to be sexually abstinent for the duration of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active treatment arm
Valsartan at a dosage and frequency titrated to blood pressure with 80mg or 160mg tablets up to a maximum dose of 160mg b.i.d.
|
At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria. Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d. |
Placebo Comparator: Placebo arm
Matching 80mg or 160mg placebo tablets at a dosage and frequency titrated to systolic blood pressure
|
At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
first occurrence of intensive care unit admission, mechanical ventilation or death
Time Frame: within 14 days
|
Death is defined as all-cause mortality
|
within 14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Death
Time Frame: Within 14 days, 30 days, 90 days and at 1 year
|
All-cause mortality; and time to all-cause mortality
|
Within 14 days, 30 days, 90 days and at 1 year
|
Mechanical ventilation
Time Frame: within 14 days
|
Occurrence of mechanical ventilation and time to ventilation
|
within 14 days
|
Intensive care unit admission
Time Frame: within 14 days
|
Occurrence of ICU admission and time to admission
|
within 14 days
|
Occurrence of acute kidney injury
Time Frame: Within 14 days
|
Defined as a 50% decline in estimated glomerular filtration rate relative to baseline, or decrease of >30 ml/min/1.73m2
and to a value below 60 ml/min/1.73m2
|
Within 14 days
|
Collaborators and Investigators
Investigators
- Study Chair: Niels van Royen, MD PhD, Radboud University Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- Severe Acute Respiratory Syndrome
- COVID-19
- Syndrome
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Valsartan
Other Study ID Numbers
- NL73547.091.20
- 2020-001320-34 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Acute Respiratory Syndrome
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory Distress SyndromeFrance
-
Oneness Biotech Co., Ltd.CompletedDisease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)United States
-
NeuroActiva, Inc.UnknownSevere Acute Respiratory Syndrome | Covid19 | Corona Virus Infection | Severe Acute Respiratory Syndrome (SARS) Pneumonia | Neurodegeneration | Neuroinflammatory Response | Severe Acute Respiratory Infection | Severe Acute Respiratory Syndrome of Upper Respiratory TractUnited States
-
Wits Health Consortium (Pty) LtdFred Hutchinson Cancer Center; Janssen Vaccines & Prevention B.V.; National Institute... and other collaboratorsCompletedSARS (Severe Acute Respiratory Syndrome)South Africa
-
Hôpital Universitaire SahloulCompleted
-
TakedaCompletedPrevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Japan
-
Laboratorios Silanes S.A. de C.V.CompletedSevere Acute Respiratory Syndrome Coronavirus 2Mexico
-
Massachusetts General HospitalXijing Hospital; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Niguarda...CompletedCoronavirus | SARS (Severe Acute Respiratory Syndrome)United States, Sweden
-
Throne Biotechnologies Inc.Not yet recruitingSevere Acute Respiratory Syndrome (SARS) Pneumonia
-
University of SaskatchewanGovernment of Canada; Vaccine Formulation Institute (VFI); Government of Saskatchewan and other collaboratorsCompletedSevere Acute Respiratory Syndrome Coronavirus 2Canada
Clinical Trials on Valsartan (Diovan)
-
Mustafa Kemal UniversityNovartis PharmaceuticalsCompletedHypertension | Left Ventricular HypertrophyTurkey
-
Wake Forest University Health SciencesJohns Hopkins UniversityTerminatedHIV | Sarcopenia | Aging | Angiotensin Receptor AntagonistsUnited States
-
Hallym University Medical CenterUnknownAcute Ischemic StrokeKorea, Republic of
-
Astellas Pharma IncCompletedHealthy | Pharmacokinetics of ValsartanJapan
-
Samsung Medical CenterRecruitingHeart Failure, SystolicKorea, Republic of
-
KVT-Study GroupYokohama City University; Showa University; Kitasato University; St. Marianna University... and other collaboratorsCompletedHypertension | Chronic Kidney DiseaseJapan
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPulmonary Arterial Hypertension | Right Ventricular Dysfunction | Right Heart Failure | Pulmonary Vascular DisorderUnited States
-
LanZhou UniversityRecruiting
-
University of ZurichNovartis PharmaceuticalsCompleted